Comparison of Fc N-Glycosylation of pharmaceutical products of intravenous immunoglobulin G

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Fokkink, Willem Jan R ^a   Falck, David ^b   Santbergen, Tom C M ^a   Huizinga, Ruth ^a   Wuhrer, Manfred ^b,c   Jacobs, Bart C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN;

ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG IDENTIFICATION; FUCOSYLATION; GALACTOSYLATION; GLYCOSYLATION; LIMIT OF QUANTITATION; MASS SPECTROMETRY; SIALYLATION; CHEMISTRY; FEMALE; HUMAN; MALE;

FEMALE; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; MALE;

EID: 84949024185     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0139828     Document Type: Article

References (40)

1. Schwab I, Nimmerjahn F (2013) Intravenous immunoglobulin therapy: How does IgG modulate the immune system? Nat Rev Immunol 13: 176-189. doi: 10.1038/nri3401 PMID: 23411799
2. Leong H, Stachnik J, Bonk ME, Matuszewski KA (2008) Unlabeled uses of intravenous immune globulin. Am J Health Syst Pharm 65: 1815-1824. doi: 10.2146/ajhp070582 PMID: 18796422
3. Sewell WA, Kerr J, Behr-Gross ME, Peter HH (2014) European consensus proposal for immunoglobulin therapies. Eur J Immunol 44: 2207-2214. doi: 10.1002/eji.201444700 PMID: 24975475
4. Darba J, Restovic G, Kaskens L, de Agustin T (2012) Direct medical costs of liquid intravenous immunoglobulins in children, adolescents, and adults in Spain. J Clin Pharmacol 52: 566-575. doi: 10.1177/0091270011399575 PMID: 21593279
5. Mark SM (2011) Comparison of Intravenous Immunoglobulin Formulations: Product, Formulary, and Cost Considerations. Hospital Pharmacy 46: 668-676.
6. Hooper JA (2008) Intravenous immunoglobulins: Evolution of commercial IVIG preparations. Immunol Allergy Clin North Am 28: 765-778, viii. doi: 10.1016/j.iac.2008.06.002 PMID: 18940573
7. Beck OE, Kaiser PE (1981) Distribution of human IgG subclasses in commercial intravenous immunoglobulin preparations. A rate nephelometric method. Vox Sang 41: 79-84. PMID: 7331283
8. Martin TD (2006) IGIV: Contents, properties, and methods of industrial production-evolving closer to a more physiologic product. Int Immunopharmacol 6: 517-522. PMID: 16504913
9. Buehler AM, Flato UP, Ferri CP, Fernandes JG (2015) Is there evidence for recommending specific intravenous immunoglobulin formulations? A systematic review of head-to-head randomized controlled trials. Eur J Pharmacol 747: 96-104. doi: 10.1016/j.ejphar.2014.11.033 PMID: 25496751
10. Feldmeyer L, Benden C, Haile SR, Boehler A, Speich R, French LE et al. (2010) Not all intravenous immunoglobulin preparations are equally well tolerated. Acta Derm Venereol 90: 494-497. doi: 10. 2340/00015555-0900 PMID: 20814625
11. Siegel J (2005) The product: All intravenous immunoglobulins are not equivalent. Pharmacotherapy 25: 78S-84S. PMID: 16229678
12. Gelfand EW (2006) Differences between IGIV products: Impact on clinical outcome. Int Immunopharmacol 6: 592-599. PMID: 16504921
13. Manlhiot C, Yeung RS, Chahal N, McCrindle BW (2010) Intravenous immunoglobulin preparation type: Association with outcomes for patients with acute Kawasaki disease. Pediatr Allergy Immunol 21: 515-521. doi: 10.1111/j.1399-3038.2010.00987.x PMID: 20546528
14. Lin MC, Fu YC, Jan SL, Lai MS (2013) Comparative effectiveness of intravenous immunoglobulin for children with Kawasaki disease: A nationwide cohort study. PLoS One 8: E63399. doi: 10.1371/journal. pone.0063399 PMID: 23650564
15. Bonilla FA (2008) Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am 28: 803-819, ix. doi: 10.1016/j.iac.2008.06.006 PMID: 18940575
16. Tjon AS, Van Gent R, Geijtenbeek TB, Kwekkeboom J (2015) Differences in Anti-Inflammatory Actions of Intravenous Immunoglobulin between Mice and Men: More than Meets the Eye. Front Immunol 6: 197. doi: 10.3389/fimmu.2015.00197 PMID: 25972869
17. Kaneko Y, Nimmerjahn F, Ravetch JV (2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313: 670-673. PMID: 16888140
18. Raju TS (2008) Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 20: 471-478. doi: 10.1016/j.coi.2008.06.007 PMID: 18606225
19. Karsten CM, Pandey MK, Figge J, Kilchenstein R, Taylor PR, Rosas M, et al. (2012) Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB and dectin-1. Nat Med 18: 1401-1406. PMID: 22922409
20. Sudo M, Yamaguchi Y, Spath PJ, Matsumoto-Morita K, Ong BK, Sharizalia N, et al. (2014) Different IVIG Glycoforms Affect In Vitro Inhibition of Anti-Ganglioside Antibody-Mediated Complement Deposition. PLoS One 9.
21. Washburn N, Schwab I, Ortiz D, Bhatnagar N, Lansing JC, Medeiros A, et al. (2015) Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity. Proc Natl Acad Sci U S A 112: E1297-1306. doi: 10.1073/pnas.1422481112 PMID: 25733881
22. (1983) IUIS/WHO notice. Appropriate uses of human immunoglobulin in clinical practice. Clin Exp Immunol 52: 417-422. PMID: 6861378
23. Radosevich M, Burnouf T (2010) Intravenous immunoglobulin G: Trends in production methods, quality control and quality assurance. Vox Sang 98: 12-28. doi: 10.1111/j.1423-0410.2009.01226.x PMID: 19660029
24. Pucic M, Knezevic A, Vidic J, Adamczyk B, Novokmet M, Polasek O, et al. (2011) High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. Mol Cell Proteomics 10: M111 010090. doi: 10.1074/mcp.M111.010090 PMID: 21653738
25. Lattimore S, Wickenden C, Brailsford SR (2015) Blood donors in England and North Wales: Demography and patterns of donation. Transfusion 55: 91-99. doi: 10.1111/trf.12835 PMID: 25178387
26. Veldhuizen IJ, Doggen CJ, Atsma F, De Kort WL (2009) Donor profiles: Demographic factors and their influence on the donor career. Vox Sang 97: 129-138. doi: 10.1111/j.1423-0410.2009.01201.x PMID: 19508703
27. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, et al. (2002) Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 277: 26733-26740. PMID: 11986321
28. Bakovic MP, Selman MH, Hoffmann M, Rudan I, Campbell H, Deelder AM, et al. (2013) High-throughput IgG fc N-glycosylation profiling by mass spectrometry of glycopeptides. J Proteome Res 12: 821-831. doi: 10.1021/pr300887z PMID: 23298168
29. Parekh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A, Stanworth D, et al. (1985) Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 316: 452-457. PMID: 3927174
30. Fokkink WJ, Selman MH, Dortland JR, Durmus B, Kuitwaard K, Huizinga R, et al. (2014) IgG Fc N-glycosylation in Guillain-Barre syndrome treated with immunoglobulins. J Proteome Res 13: 1722-1730. doi: 10.1021/pr401213z PMID: 24533874
31. Farooq M, Takahashi N, Arrol H, Drayson M, Jefferis R (1997) Glycosylation of polyclonal and paraprotein IgG in multiple myeloma. Glycoconj J 14: 489-492. PMID: 9249147
32. Jefferis R (2012) Isotype and glycoform selection for antibody therapeutics. Arch Biochem Biophys 526: 159-166. doi: 10.1016/j.abb.2012.03.021 PMID: 22465822
33. Selman MH, McDonnell LA, Palmblad M, Ruhaak LR, Deelder AM, Wuhrer M (2010) Immunoglobulin G glycopeptide profiling by matrix-assisted laser desorption ionization Fourier transform ion cyclotron resonance mass spectrometry. Anal Chem 82: 1073-1081. doi: 10.1021/ac9024413 PMID: 20058878
34. von Gunten S, Shoenfeld Y, Blank M, Branch DR, Vassilev T, Käseramann F, et al. (2014) IVIG pluripotency and the concept of Fc-sialylation: Challenges to the scientist. Nat Rev Immunol 14: 349. doi: 10. 1038/nri3401-c1 PMID: 24762829
35. Schwab I, Lux A, Nimmerjahn F (2014) Reply to-IVIG pluripotency and the concept of Fc-sialylation: Challenges to the scientist. Nat Rev Immunol 14: 349.
36. Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R (2011) Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 29: 310-312. doi: 10.1038/nbt.1839 PMID: 21478841
37. Selman MH, Derks RJ, Bondt A, Palmblad M, Schoenmaker B, Koeleman CA, et al. (2012) Fc specific IgG glycosylation profiling by robust nano-reverse phase HPLC-MS using a sheath-flow ESI sprayer interface. J Proteomics 75: 1318-1329. doi: 10.1016/j.jprot.2011.11.003 PMID: 22120122
38. Einarsdottir HK, Selman MH, Kapur R, Scherjon S, Koeleman CA, Deelder AM, et al. (2013) Comparison of the Fc glycosylation of fetal and maternal immunoglobulin G. Glycoconj J 30: 147-157. doi: 10. 1007/s10719-012-9381-6 PMID: 22572841
39. Wuhrer M, Stam JC, Van de Geijn FE, Koeleman CA, Verrips CT, Dolhain RJ, et al. (2007) Glycosylation profiling of immunoglobulin G (IgG) subclasses from human serum. Proteomics 7: 4070-4081. PMID: 17994628
40. Zauner G, Selman MH, Bondt A, Rombouts Y, Blank D, Deelder AM, et al. (2013) Glycoproteomic analysis of antibodies. Mol Cell Proteomics 12: 856-865. doi: 10.1074/mcp.R112.026005 PMID: 23325769